Improving Patient Outcomes Through Data

Cardiovascular Tools in CPCI DRVS ASCVD and Hypertension

December 3, 2020



Contact Information





LuAnn Kimker, RN, MSN Vice President of Clinical Innovation LuAnn.Kimker@azarahealthcare.com



Russell James Manager, Business Intelligence Trillium Health



Molly Wack Client Success Coordinator Molly.Wack@azarahealthcare.com

Maximize Your Experience!





Ask questions using the Q&A box.



You will remain muted throughout.



Don't try to multitask.



Participate in the polls!

Topics for Today's Session



Introduction

Hypertension Control in CPCI

Managing Hypertension


ASCVD in DRVS

Point of Care Tools

Clinical Application



azarahealthcare.com




Preventing 1 Million Heart Attacks and Strokes. Centers for Disease Control and Prevention website. https://www.cdc.gov/vitalsigns/million-hearts/. September 2018. Accessed October 14, 2019.

Trends in Blood Pressure Control among US Adults: Progress Lost



BP Control, SBP<140 mmHg & DBP<90 mmHg: 1999-2000 through 2017–2018 NHANES data analysis




Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, Colantonio LD. Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018. *JAMA*. Published online September 9, 2020. doi:10.1001/jama.2020.14545

Go to www.menti.com and use the code 4677499

What is the Hypertension BP Control Level (<140/90) at your CHC?







azara

azara


HTN Controlling High BP (eCQM 165v8) - CPCI azara healthcare 80% Control across all **Best DRVS Center DRVS** Centers centers in DRVS 5 4 4 Δ Number of Centers 3 3 3 3 2 2 2 2 2 2 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 45% 50% 55% 60% 65% 70% 75% 80%

% Control

HTN Controlling High BP - CPCI



CMS 165v8 - Patients 18-85 years of age who had an active diagnosis of hypertension during the measurement period and whose most recent blood pressure during the measurement period was adequately controlled (<140/90mmHg).



Getting to Control


Using DRVS Tools





Tools to Help You Get to BP Control





Hypertension Specific Measures




CVD Prevention and Control (1815) i				FILTER A	:	57
PERIOD CENTERS RENDERING PROVIDER USUAL PROVIDER TY November 2020 All Centers All Rendering Provid All Usual Provider	~		+	- Add Filter	🗘 Upda	te
REPORT		C	CARE GAPS			
GROUPING No Grouping ~ TARGETS Primary Secondary	Not Met		REPOR	FORMAT Scorec	ard	~
MEASURE	RESULT	TARGET	NUMERATOR	DENOMINATOR	EXCLUSIONS	
i Undiagnosed HTN	3.0%	2.0%	18,176	605,159	32,331	±
i) HTN Prevalence	29.1%	Not Set	176,189	605,159	32,331	±
Hypertension Controlling High Blood Pressure (CMS165v8)	61.6 %	61.2%	109,014	176,984	5,350	±
(1) Statin Therapy for the Prevention and Treatment of Cardiovascular Disease (CMS347v3)	70.1%	80.0%	88,216	125,860	4,806	Ŧ

Which measures are most important to track for your Center? Performance Reporting or Reporting for Action?

azarahealthcare.com

AMA MAP BP Quality Improvement Framework

All three are critical for control.



Boonyasai, RT, Rakotz, MK, Lubomski, LH, et al. Measure accurately, Act rapidly, and Partner with patients: An intuitive and practical three-part framework to quide efforts to improve hypertension control. *J Clin. Hypertens*, 2017: 19: 684–694. https://doi.org/10.1111/ich.12995

MAP BP Measures



Measure Name	Description
Controlling High Blood Pressure (CMS165v8, NQF 0018, ACO 28)	Patients 18-85 years of age who had an active diagnosis of hypertension during the measurement period and whose most recent blood pressure during the measurement period was adequately controlled (<140/90mmHg).
HTN - Confirmatory Repeated Blood Pressure Measurement	Encounters in the measurement period where patients with essential hypertension and uncontrolled blood pressure (>140/90) had a confirmatory blood pressure measured at the visit.
HTN - Medication Intensification	Encounters in the measurement period where patients with essential hypertension and uncontrolled BP (>140/90) had a new class of BP medication prescribed.
HTN - Average Systolic BP Reduction After Medication Intensification	The average systolic blood pressure reduction for patients with uncontrolled blood pressure after receiving medication intensification at an encounter in the period.

Available upon request

HTN Controlling High Blood Pressure | CMS165v8

- Changed to include all patients with an active diagnosis of HTN in the year as opposed to only including those with active diagnoses in the first 6 months of the year.
- IMPACT: Denominators will likely go up and your numerator may not keep pace which could equate to lower results / percentages.



REMOTE MONITORING



The measure does make mention of Remote Monitoring, but ONC has provided guidance.

- Patient submitted BP must be transmitted electronically or where the reading is taken digitally and the provider can see the digital readout / results.
- Historical BPs must be able to be reviewed via the device used to show a practitioner.

Record this data in same place where you document in person vitals. Designate as remote monitored or evidence found in type of visit i.e., telehealth.

		e <mark>st challenges</mark> ggest challenges r		
patient complic	hypterension?			med
	patient compliance	Getting accurate bp	patients being adherent to med regimen	
An extensive po patients with nu impacting life c	An extensive panel of complex patients with numerous SDOH	medication nonadherence	second reading not done COVID /	COVID / lon't have
	impacting life choices	compliance to medication, having them return for follow-up, education	Video visits most patients don't have self monitor	
televisits and m patients do not	televisits and monitoring BP - most patients do not have BP machines	for pateint		




.

Go to www.menti.com and use the code 46 77 49 9

Have You Applied for the HRSA funding for FY2021 National Hypertension Control Initiative Supplemental



Funding for H(Have You Applied for the HRSA funding for FY2021 National Hypertension Control Initiative Supplemental Funding for Health Centers ?



Activities by Role | Summary



Role	Activities
MA/LPN	 Pre-visit plan for telehealth /face to face patient visits Take confirmatory BPs for any BP >140/90 Discuss alerts in huddle Elevated BP and no HTN dx Missing ASCVD criteria No Statin No Self-Management
RN	 Schedule BP follow up within 2 weeks of medication change Conduct virtual BP check (visit or home BP monitoring results) Provide home BP monitoring instruction/teach back Evaluate/Identify clinical inertia when conducting prescription refills
Pharmacist	 Review/discuss/manage patients with treatment inertia Participate in Care Team huddles
Medical Provider	 Utilize evidence-based guidelines for treatment intensification Diagnose the undiagnosed Review MAP hypertension management dashboard Review uncontrolled patients on panel Use ASCVD Risk Registry to guide treatment when labs returned Collaborate with care team and facilitate warm hand-offs for more in-depth education

Activities by Role | Summary (con't)



Role	Activities
Care Manager	 Actively oversee/manage patients with changes in medication (cohort) Provide home BP monitoring instruction/teach back Self management goal setting / care planning Conduct SDOH screens Provide education or enabling resources Participate in Care Team huddles
Registered Dietitian	 Self management focus on nutrition and weight loss Identify patients with out-of-range BMI Participate in Care Team huddles
Care Coordinator/ CHW	 Identify patients with undiagnosed hypertension, high risk ASCVD without treatment, hypertensive tobacco users
Front Office or Call Center	 Schedule visits for hypertensive patients with no follow up appointments (or others as identified by Care Coordinator/CHW/Care Manager)
Quality Improvement Team	 Review panel reports with providers (academic detailing) Monitor practice, team, provider performance Create cohorts based on focus for intensification, pharmacy intervention, care manager engagement







ASCVD 10-year Risk Calculator



GOAL: Aide in the prevention or delay of ASCVD and related conditions by estimating the risk of developing ASCVD based on certain demographics, lifestyle choices, diagnoses, medications, and vitals.

10-year risk of developing a first ASCVD event

- Non-fatal myocardial infarction
- Coronary heart disease death
- Fatal or nonfatal stroke

Funding for this project was made possible by the New York State Department of Health (NYSDOH)

azarahealthcare.com

Calculator | Inclusion and Exclusion



- Include:
 - Patients age 40-80



- Exclude:
 - Patients with evidence of ASCVD
 - Previous myocardial infarction, stroke, CABG, stent, etc.
 - Highest lifetime LDL >190
 - Familial hypercholesterolemia




Calculator | Elements of Calculation Total Cholesterol Most recent in past 5 years HDL-C Cholesterol Systolic Blood Pressure Most recent in past 2 years Smoking Status Treatment for High Blood Pressure Active Hypertension Medication Active in last 365 days

Diabetes Diagnosis

azarahealthcare.com

Patient Populations






Race

Do you currenty use ASCVD risk to determine patient treatment?

Do you currenty use ASCVD risk to determine patient treatment?





azara

ASCVD Risk Registry



ATE RANGE 09/14/2020-09/21/2020		NG PROVIDER ering Provid	~									+	Add Filter	🗘 Upda	
			REGISTRY				_			8	VALUE SETS				
Search Patients				٩											
EMOGRAPHICS >	1		ASCVD			CHOLESTER	OL	HDL		BP			HTN MED		
AME	MRN	AGE	RISK	NA REASON	RISK SCORE	DATE	RESULT	DATE	RESULT	DATE	SYSTOLIC	DIASTOLIC	START DATE	STOP DATE	
		6	3 High		29.86	8/17/2017	210	8/17/2017	163.00	9/16/2020	163	98	9/16/2020		
		5	7 N/A			6/1/2020	171	6/1/2020	66.00	s Risk L	.evel	Numeri	c Score		
		4			2.88	3/15/2017	204	3/15/2017	53.00	Low F	Risk	<5%			
		5			5.54	2/26/2020	231	2/26/2020	63.00	9	-				
		4			1.11	9/3/2019	150	9/3/2019	60.00	Borde	erline Risk	5%-<7.5	5%-<7.5%		
		6	9 N/A 4 Missing Data			7/22/2020	183	7/22/2020	44.00	Inter	Intermediate				
			Thissing Udid							Risk		7.5%-<2	20%		
Contair	ns AS	CVD	risk sco	ore and	level, S	SDOH	and			High	Risk	>=20%			
annoin	tmen	t det	ails							Missi	ng Data	-	any calcula	ation	
Sort by						•••					0	elemen	ts		


ASCVD Risk Registry



		ASCVD Ten Year Risk (REGISTRY DATE RANGE 12/02/2020-12/02/2020 🚔 Today		Tor	morrow. ther by	. Narrow re	e Range for Iarrow results ovider or care hager.				
	ASCVD	Tomorrow	СН	OLESTER	ROL	HDL		ВР			HTN MED
AGE	RISK 7 ↑	Yesterday	DAT	ТЕ	RESULT	DATE	RESULT	DATE	SYSTOLIC	DIASTOLIC	START DATE
42	Missing Data	Last 7 Days						1/28/2019	119	72	
46	Missing Data	Last 30 Days									
42	Missing Data	This Month	2/3	/2020	151	2/3/2020	25.00	10/26/2020	154	88	10/26/2020
55	Missing Data	Filter ASCVD Risk						9/15/2020	142	87	
46	Missing Data	column to						10/8/2018	135	93	6/26/2018
66	Missing Data	"Missing Data".						12/6/2019	134	77	2/27/2018
51	Missing Data							8/21/2019	142	92	7/18/2017
57	Missing Data							12/4/2019	123	80	6/28/2019
48	Missing Data					What crite	aria aro	2/19/2020	120	82	5/30/2019
↓ 1 to 9	of 78					they mis					< < Page 1 of 9 > >I

Tools to Help You Get to BP Control





PVP Alerts at Point of Care



	ASCVD Risk Calculator Data Missing	Alert will trigger for patients age >= 40 and age <80 that do not have clinical atherosclerotic cardiovascular disease (ASCVD) who are missing data for the required components of the ASCVD Risk Calculator. This alert is not configurable.
TURN IT ON!	Elevated ASCVD Risk & Statin Rx	Alert will trigger for patients age >= 40 and age <80 that have not been prescribed statin medication with an elevated risk of atherosclerotic cardiovascular disease (ASCVD) as determined by a risk score >= 7.5%. This alert is not configurable
	Statin Rx	Alert will trigger for patients age >= 22 that have not been prescribed statin medication AND that have any of the following conditions: ASCVD, LDL>190, pure or Familial Hypercholesterolemia, OR diabetes with an LDL of >=70. This alert is not configurable
	BP High No Dx	Alert will trigger if a patient has had 2 BP readings in the past year with a systolic >= 140 OR diastolic >=90. Alert only applies to patients 18 - 85 years old. Excludes patients which have ESRD, hypertension, or pregnancy. This alert is not configurable
	BP	Alert will trigger if Blood Pressure has not occurred in the last 365 days, or if numeric_1 value is >= 140 and numeric_2 value is >= 90. Alert only applies to patients <= 85 yrs old. Patient must have IVD and AMI and CABG or PCI and Hypertension and Diabetes.
TURN IT ON!	Self-Management	Alert will trigger if Self Management Plan has not occurred in the last 1 years or is due in the next 3 month. Alert only applies to patients >=18 yrs old. Patients must have Hypertension

azarahealthcare.com


Alerts for Hypertension – Enabled in CPCI





49 Health Centers

Alerts Enabled by Center




healthcare

azarahealthcare.com

6

Alert Closure | ASCVD Missing & Statin Rx





azarahealthcare.com

Dig a Little Deeper...




What do you expect to happen at specific visit types?

АРРТ	АРРТ			г	1		1	ORIGINAL			
DATE	ТҮРЕ	REASON	STATUS	SERVICE LINE	WALKIN	SAME DAY	ALERT NAME	ALERT MESSAGE	RESULT DATE	RESULT	NUMERATOR 7
11/2/2020	OVP	fasting DM check	Checked In	Primary Care	N	N	Self Mgmt Plan	Missing			N
11/2/2020	OVE	DM follow up	Checked In	Primary Care	Ν	Ν	BP	Overdue	8/20/2019	120/70	N
11/2/2020	OVE	DM follow up	Checked In	Primary Care	Ν	N	Self Mgmt Plan	Missing			N
11/2/2020	SDACUTE	pain on side	Checked In	Primary Care	N	Ν	Self Mgmt Plan	Missing			N
11/5/2020	OVC	DM check	Checked In	Primary Care	Ν	N	Self Mgmt Plan	Missing			N
11/6/2020	OVE	PT IS HAVING PAIN IN HER LEFT ARM AND IS WANTING A	Checked In	Primary Care	N	Ν	Self Mgmt Plan	Missing			N
11/2/2020	OVC	ER follow up for sugars. Okayed per Letti	Checked In	Primary Care	N	N	Self Mgmt Plan	Missing			N
11/5/2020	OVC	3 month follow up on DM	Checked In	Primary Care	Ν	Ν	Self Mgmt Plan	Missing			N
11/3/2020	TeleMedest	fever	Checked In	Primary Care	N	N	BP	Overdue	11/4/2019	130/80	N
11/2/2020	OVE	REFILLS	Checked In	Primary Care	N	Ν	BP	Overdue	5/7/2019	140/94	N
11/2/2020	OVE	Copd f/u	Checked In	Primary Care	Ν	N	Self Mgmt Plan	Missing			N
11/3/2020	OVE	back pain	Checked In	Primary Care	N	Ν	Self Mgmt Plan	Missing			N
11/2/2020	OVE	discuss labs	Checked In	Primary Care	N	Ν	Self Mgmt Plan	Missing			N
11/6/2020	SDACUTE	cough, wheezing (covid test negative)	Checked In	Primary Care	N	Ν	Self Mgmt Plan	Missing			N
11/2/2020	OVE	gave consent, provided with number, 1 month f/u	Checked In	Primary Care	N	N	Self Mgmt Plan	Missing			N
11/4/2020	OVE	refills	Checked In	Primary Care	Ν	Ν	Self Mgmt Plan	Missing			Ν

BP at Every Visit





azara **Confirmatory BP Measurement** healthcare HTN-Confirmatory Repeated Blood Pressure Measurement (i) Ż FILTER A ē MEASURE PERIOD RENDERING PROVIDER RACE RENDERING LOCATION + Add Filter ∇ 🖒 Update August 2020 $\sim \mathbf{X}$ 3 selected ~ (**X**) All Rendering Provid... 4 selected \sim \sim DETAIL LIST **VALUE SETS** MEASURE ANALYZER Last Processed 9/5/2020 **Targets & Metrics** \sim 10% Center Average SELECTED 255 Baseline **913** TARGET MAP Metrics 100 / 1,013 \sim 10% + 10% 4% Network Average August 2019 **12 Exclusions** 3ENC Gaps • PRIMARY 35% • SECONDARY 25% To Target 31% Best Center Ċ. Aug 20 GROUP BY Rendering Location Group Comparison Ö GROUP BY Race 2ND None Selected \sim 25% 100% 22% 90% 20% 20% 20% 80% 70% 15% 60% 50% 10% 40% 30% 5% 20% 10% 0% 0% 40020 Jul 20 589 00,19 401 0 000,19 Jan 20 Mar 20 20/20 May 20 Jun 20 AU920 Asian 2 White Black Africa. More than On. QUA 📕 MAP - Facilitated 📕 MAP - Self-Guided 📕 Primary Care 0000 N Ħ Baseline 0000

Care Management Passport (CMP)



		Sex at Birth: F	Phone:		Last Phys: 3/4/2	2020	PCP:	
IRN:		GI: Female	Language: English		Portal Access: N	N	Payer: AETN	A (MEDICARE REPLACEMENT PPO)
OB:	(68)	SO: Choose not to disclose	Risk:				Care Manag	er: HUMANA PHARMACY, INC.
Assessme	nts (Last 10 of 42)				Active Problems (Last 10 of 12)		
CODE	DESCRIPTION		LAST ASSESSED	#	CODE	DESCRIPTION		MOST RECENT
Z71.3	DIETARY COUNSEL	9/10/20	5	73211009	Diabetes mellitus (disor	der)	12/10/19	
K21.9	Gastro-esophageal	9/10/20	3	95319004	Skin nodule	11/5/18		
E78.5	Hyperlipidemia, un	9/10/20	4	162864005	Body mass index 30+ - o	8/11/16		
G47.00	Insomnia, unspecifi	9/10/20	2	9014002	Psoriasis	8/11/16		
R32	Unspecified urinary	y incontinence	9/10/20	1	399153001	Vertigo	8/11/16	
R73.9	HYPERGLYCEMIA, U	UNSPECIFIED	9/10/20	2	165232002	Urinary incontinence		5/2/16
Z71.89	Other specified cou	unseling	9/10/20	5	193462001	Insomnia		5/2/16
Z68.34	Body mass index (B	3MI) 34.0-34.9, adult	9/10/20	5	371081002	Arthritis of knee		5/2/16
110	ESSENTIAL (PRIMA	RY) HYPERTENSION	9/10/20	2	55822004	Hyperlipidemia		5/2/16
Z76.0	Encounter for issue	e of repeat prescription	9/10/20	1	235595009	Gastroesophageal reflux	x disease	5/2/16
Encounte	rs (Last 5 of 23)				The Numbers		BP Trending	g Up
DATE	PROVIDER	ТҮРЕ	REASO	N	BMI	9/10/20	34.5 lb/m2	
9/10/20		ESTABLISHED PATIEN	Т		Custolia	0/10/20	150 mml/c	
4/20/20		TeleMed15			Systolic	9/10/20	159 mmHg	
4/15/20		TeleMed15			Diastolic	9/10/20	85 mmHg 📃 🔍	1 mar

CMP (Con't)




• DOS 9/10/20

- Follow up appointment in one Month
- 6-month prescription with no intensification
- Has insurance but SDOH risk with FPL<200%

Appointments (1)												
DATE	PROVIDER TYPE REASON											
10/15/20	ESTABLISHED PATIENT											
Social Determinants of Health (2)												
FPL<200%	INSURANCE											
Allergies (3, last re	viewed 1/10/17)											
START	DESCRIPTION REACTION SEVERITY											
1/10/17												
4/22/16	INFLUENZA A (H1N1)											
4/22/16	PENICILLINS											
Medications (Last 10 of 138)												
ACTIVE AS OF	NAME											
9/11/20	amitriptyline HCl 50 MG Oral Tablet											
9/10/20	valsartan 160 MG Oral Tablet											
9/10/20	oxybutynin chloride 10 MG 24HR Extended Release Oral Tablet											
9/10/20	Famotidine 20 MG Oral Tablet											
9/10/20	atorvastatin 10 MG Oral Tablet											
9/10/20	amitriptyline HCl 50 MG Oral Tablet											
9/10/20	Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT											
4/14/20	Ventolin HFA 0.09 MG/ACTUAT Metered Dose Inhaler, 200 ACTUAT											
3/4/20	valsartan 160 MG Oral Tablet											

Clinical Inertia | Upcoming Appointments



azara

azarahealthcare.com

Treatment Opportunities



RIOD			NDERING PR	OVIDER RENDERING I	OCATION	SERVICE LINES								
Y August	2020		All Rendering P		~ ×	Primary Care	~ 🗵						+ Add Filter	🗘 Update
		.al N	1EASURE AN	ALYZER			i Det	TAIL LIST				VALU	JE SETS	
Searc	h Patients .				٩	All	Gaps	Num Ex	cl					
DE >			ENCOUNT	ER		RENDERING	NEXT APPO	INTMENT		1				HTN
NAME	MRN	AGE	DATE	LOCATION	TELEHEALTH	PROVIDER	DATE 🗸	PROVIDER 🗸	SBP	DBP	INTENS ENC DATE	DRUG CLASS	PRESCRIPTION $\downarrow \equiv$	DIAGNOSIS
		63	6/25/20	Adult Medicine	Ν	SHORTER, JA	10/1/2020	SHORTER	160	68				1/12/2017
		66	7/29/20	Family Medicine - Pinewo	Ν	SAUNDERS, K	9/29/2020	SAUNDER:	152	62				8/17/2016
		66	6/9/20 1	Family Medicine - Pinewo	Ν	SAUNDERS, K	9/29/2020	SAUNDER:	232	70				8/17/2016
		63	6/9/20 1	Adult Medicine	Ν	SHORTER, JA	9/14/2020	SHORTER,	142	98				5/11/2018
		63	7/15/20	Family Medicine - Pinewo	Ν	SAUNDERS, K	9/16/2020	SAUNDER:	142	80				3/6/2018
		52	6/16/20	Adult Medicine	Ν	SHORTER, JA	9/16/2020	SHORTER,	122	92				7/5/2017
		55	6/18/20	Adult Medicine	Ν	BRANT, RUSS	9/18/2020	BRANT, RL	120	90				11/4/2016
		39	6/12/20	Adult Medicine	Ν	SHORTER, JA	9/15/2020	SHORTER,	148	90				9/11/2014
		56	6/4/20 1	Adult Medicine	Ν	SHORTER, JA	9/16/2020	SHORTER,	140	80				2019
		53	7/29/20	Adult Medicine	Ν	ASHLEY, JON	9/29/2020	ASHLEY, JC	150	90	Filtory	Drimary	Sara Canc-N	017
			8/6/20 1	Adult Medicine	N	ASHLEY, JON	9/25/2020	ASHLEY, JONATHAN	124	90	Filter:	Primary C	Care, Gaps, Ne	2XL 019

Clinical Application

Russell James

Manager, Business Intelligence Trillium Health



Go to www.menti.com and use the code 4677499



azara

7


How good was your guess?

How good was your guess?



Tools to Help You Get to BP Control





R03.0 - Elevated blood-pressure reading, without diagnosis of hypertension. What guidelines do you have or follow for the using RO3.0?

l don't know.		Automatically diagnos as HTN	Not sure
Varies by provider and Patient		No real guidelines at all	

Press ENTER to pause scroll



Undiagnosed Hypertension



Undiagnosed HTN - Million Hearts (i) MEASURE FILTERS: TY November 2020 American Indian/Alaska Native MEASURE ANALYZER	Who do we reach out to?		68 w/elevated BP Dx R03.0			85 P Dx R0	93.0	:
Targets & Metrics -7% + Baseline TY November 201	553 / 10,269 9 ~ 52 Exclusions	MH Goals PRIMARY	1% 🗿 SECONDARY 4%	45(To Targ	нмакк	5% Cente	ork Average	
TY 11/20 GROUP BY	Race ~		GROUP BY Sex At Birth	▼	2ND Race			¢
20% 18% 16%		SEX AT BIRTH	RACE	RESULT	CHANGE	NUM 203	NOM ↑ 3,853	EXCL 22
14% 11% 13% 12% 12% 12% 11%	13%	М	White	8%	- 8% 🔻	232	2,780	1
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	9% 8% 7% 7% 7	6 F	Black/African American	4%	- 5% 🔻	39	1,047	19
	5% 5% 4% 4% 4	м	Black/African American	5%	- 7% 🔻	47	965	1
2% 0% 0% 0% 0% 0%		F	Unreported/Refused t	1%	- 7% 🔻	8	755	6
0%	HIND HORD HORD HIDE HILLE	м	Unreported/Refused t	3%	- 10% 🔻	17	636	0
4° 4° 4. 4. 4. 4. 4. 4.	4 4 4 AN AN		Asian	1%	- 8% 🔻	1	92	0
American Indian/Alaska Native Asian Black/Africar	American Pacific Islander	F	Asian	4%	0%	4	91	2
		M	American Indian/Alas	5%	- 5% 🔻	1	19	0
Unreported/Refused to Report Race	White	U	White	0%	0%	0	10	0

Hypertension Registry



Evaluate BP over time and medication treatment or self-management

HTN DX		BP			BP 2ND MOST RECENT BP 3RD MOST RECENT			STATIN MED	ACE ARB				
DATE 个	CODE	DATE	SYSTOLIC	DIASTOLIC	DATE	RESULT	DATE	RESULT	START DATE	RXNORM	NAME	START DATE	STOP
11/25/2020	110	11/25/2020	151	95	10/12/2020	126/85	8/12/2020	131/85	8/16/2020	617311	atorvastatin 40	11/25/2020	
11/24/2020	110	11/24/2020	150	92	10/27/2020	145/89	10/15/2020	174/83					
11/22/2020	59621000	11/20/2020	215	119									
11/13/2020	110	11/13/2020	128	98	10/27/2020	125/90	10/16/2020	125/86					
11/12/2020	110	11/12/2020	130	84	10/1/2020	127/80	8/27/2020	119/76					
11/9/2020	110	11/9/2020	148	89	7/9/2020	137/83	1/29/2020	147/83	9/20/2017	617318	atorvastatin 20	11/9/2020	
10/27/2020	59621000	11/25/2020	140	74	10/27/2020	124/72			9/28/2020	617312	atorvastatin 10	9/28/2020	10/28,
10/27/2020	59621000	10/27/2020	166	90								10/27/2020	
10/20/2020	110	11/25/2020	137	89	10/20/2020	154/96	1/28/2019	130/87				10/20/2020	
9/16/2020	59621000	9/30/2020	114	85	9/16/2020	202/120						9/16/2020	
9/11/2020	59621000	9/15/2020	105	73	9/11/2020	130/83	2/28/2020	120/86					
9/2/2020	59621000	11/24/2020	133	81	11/3/2020	160/70	10/16/2020	132/54				9/25/2020	
(•

Care Manager | Who Needs to Be Monitored? azara

HTN-N MEASUR		n Intensif	ication 🕦										Ŧ	FILTER ^	
PERIOD														√ Update	
TY August	t 2020	~ /	All Rendering F	Provid ~ 3 sel	lected	 Primary 	Care	\sim \otimes					+ Add Filter	♥ Update	
		all N	1EASURE AN	ALYZER				E DETAIL LIST				VALUE SETS			
Sear	ch Patients .				Q		All	Gaps Num	Excl						
Jean	chirations.	te ::			~										
DE >	I		ENCOUNT	ER		RENDERING	NEXT APPO	DINTMENT	I	1	1	1	L	HTN	
NAME	MRN	AGE	DATE	LOCATION	TELEHEALTH	PROVIDER	DATE 🔽	PROVIDER 🗸	SBP	DBP	INTENS ENC DATE	DRUG CLASS	PRESCRIPTION ↓	DIAGNOSIS DATE	
		56	6/1/20 1	Adult Medicine	N	ASHLEY, JON	10/2/2020	ASHLEY, JON	144	90	6/1/2020	420150	valsartan 80 mg tablet	4/24/2018	
		56	7/28/20	Adult Medicine	N	ASHLEY, JON	9/29/2020	ASHLEY, JON	152	100	7/28/2020	413562	spironolactone 25 mg	2/23/2017	
		65	6/3/201	Family Medicine	N	SAUNDERS, K	9/15/2020	SAUNDERS, K	170	100	6/3/2020	390123	metoprolol succinate	5/24/2017	
		74	7/2/20 1	Adult Medicine	Ν	BRANT, RUSS	9/28/2020	BRANT, RUSS	120	98	7/2/2020	606974	losartan 50 mg tablet	9/4/2019	
		Б.ve	duata	time from		SHORTER, JA	9/28/2020	SHORTER, JA	178	98	8/19/2020	423389	losartan 50 mg tablet	7/8/2019	
		Evaluate time from					9/23/2020	BRANT, RUSS	128	94	6/19/2020	398955	losartan 50 mg tablet	10/3/2016	
	intensification to next						9/17/2020	ASHLEY, JON	152	80	6/17/2020	404211	losartan 25 mg tablet	4/7/2017	
	appointment					ASHLEY, JON	7/2//2020	A SHEET, SOIL	152	00	0/2//2020	101222	tosurturi 25 mg tubtet	4,772017	

SHORTER, JA

BRANT, RUSS

SHORTER, JA

148

160

146

80

110

88

8/12/2020

7/9/2020

8/17/2020

423967

390390

409678

SHORTER, JA...

BRANT, RUSS

SHORTER, JA...

9/22/2020

9/15/2020

9/14/2020

2/13/2019

8/28/2019

10/3/2019

lisinopril 5 mg tablet

lisinopril 20 mg tablet

lisinopril 10 mg tablet

31 7/9/20 1...

8/17/20 ...

56


Adult Medicine

Adult Medicine

Ν


N

Medication Intensification | Provider Variation azara




Tools to Help You Get to BP Control





Provider / Practice Detailing



azara

azarahealthcare.com

Track Improvement with Cohorts

- Identify specific patients to track outcomes
 - Uncontrolled BP
 - High Risk ASCVD and no treatment
 - Patients with clinical inertia
 - Undiagnosed HTN
- Monitor improvement over time based on interventions







Improvement in Undiagnosed HTN



Investigate those not diagnosed. How quickly do pts convert?

d Undiagnosed HTN - Million Hearts (i) MEASURE						₹ FILTER ∧	:
PERIOD RENDERING PROVIDER COHORT TY October 2020 v 2 selected v Undx HTN 2019 v						+ Add Filter	🗘 Update
	i det	AIL LIST			VALUE SETS	5	
Targets & Metrics						Last Processed 11/7/2	2020 🕓 🗸
age 37% -46% ➡ Baseline TY October 2019		L / 723 clusions	Create Target	Венснимак	10% Center Ave7% Network Ave2% Best Center	erage	
TY 10/20 GROUP BY No.	one v 🔅	Comparison GROU	P BY Provider - Rendering	2ND None S	elected ~		٥
100% 93% 93% 87%		DERING PROVIDER	RESULT CHAN	GE NI	JM DENON	I↑ EXCL	1
90% 83% 81% 81% 80%			42%	- 38% 🔻	34	81	0
70% 61%			41%	- 43% 🔻	26	64	1
60% 50%	55% 50% 45%		49%	- 34% 🔻	24	49 47	0
40%	37%		49%	- 33% 🔻	20	47	0
30% 20%			35%	- 55% 🔻	15	43	0
10%			39%	- 43% 🔻	16	41	0
	p nº nº nº		38%	- 46% 🔻	15	40	0
4-13019 11-2119 11-2119 11-210 12-210 12-310 12-510 12-510 12-510 12-510	49/00 H9/00 H2010		30%	- 63% 🔻	12	40	0
			36%	- 53% 🔻	14	39	1
Baseline	~~ 000	Enzenverger, Jusine/N	39%	- 43% 🔻	15	38	0

azarahealthcare.com

N1219 N2209 N209 N209 N209 N309 NAD NS09 NOR ND0 N00 N00 N909

PERIOD

0.00

-2.00 -4.00

-6.00 -8.00


-10.00

-12.00

-14.00

-15.16

712019



-15.16

12020

Reduction in Systolic BP




5

Ö.

🖒 Update

Low Moderate High

Level of Care



azara

Controlling BP | Race and ASCVD

healthcare Hypertension Controlling High Blood Pressure (CMS165v8) Ś FILTER A MEASURE RACE PERIOD **RENDERING PROVIDER** SERVICE LINES + Add Filter ∇ 🖒 Update ~ (X) TY August 2020 All Rendering Provid... Primary Care 4 selected \sim \sim \sim **VALUE SETS MEASURE ANALYZER** DETAIL LIST **Targets & Metrics** Last Processed 9/5/2020 () \sim **56%** Center Average SELECTED Baseline 4,248 TARGET 2,331 MAP Metrics 5,341 / 9,589 \sim 56% -2% 4 **50%** Network Average TY August 2019 133 Exclusions Gaps To Target • PRIMARY 80% • SECONDARY 70% 70% Best Center Ċ. TY 8/20 GROUP BY Race Ċ. Comparison GROUP BY ASCVD Risk Score 2ND Race \sim 75% 100% 90% 70% 69% 70% 80% 66% 70% 64% 65% 63% 63% 62% 62% 62% 62% 60% 61%61% . 59% 59% 59% 50% 60% 58% 58% 57% 40% 54% 30% 55% 52% 52% 20% 50% 10% 0%-20th 45% HIGH ×1 8/19 ~~ 9/19 r4 10/19 F4 11/109 7 12/19 718120 × 3120 × 4120 TY 120 TY 220 x 520 x 620 x 120 Asian 📕 Black/African American 📕 More than One Race 📃 White Asian 📕 Black/African American 📕 More than One Race 🚽 White N 0000 Baseline oool

azara

Go to www.menti.com and use the code 4677499

Additional Training Needs







Resources







PDF

Resource Library: M.A.P. BP Program



Steps for In-Office BP Readings <u>https://bit.ly/3iu6Fjb</u>

Poster to help educate the care team on how to correctly take an in-office BP measurement.





Hypertension Medication Treatment Protocol https://bit.ly/3c5374w PDF Provides guidance on antihypertensive medication treatment for patients

with hypertension to help get them to goal.

Act registry Bost sectors

Act Rapidly Best Practices <u>https://bit.ly/2FxzvAD</u> PDF

Summary of recommendations to help improve diagnosing and managing high BP. Use after completing the Act Rapidly Pre-assessment.



Partner with Patients Best Practices https://bit.ly/35wEAUF PDF

Summary of recommendations for communicating with and engaging patients. Use after completing the Partner with Patients Pre-assessment.

Partner with patients: (Nop or object Dear Start Physical Start P

Identify how your health center can improve communicating with and engaging patients.



Find more resources for the American Medical Association's M.A.P. BP Program at: <u>https://bit.ly/35GbQZP</u>



Care team


Care team

azarahealthcare.co

azarahealthcare.com

DRVS Resources

- ASCVD User Guide
- ASCVD 10-Year Risk Calculator Overview Video
- Quick Tip Clips
 - <u>Alert Admin</u>
 - <u>Cohorts</u>
 - -<u>PVP / CMP</u>
- DRVS Dashboards User Guide
- For more information on
 - Access to the MAP measures, contact Azara Support
 - Access to AMA's program, contact LuAnn Kimker





Questions?





Upcoming Webinars



Capturing and Using SDOH

Tuesday, December 8 2:00 – 3:00 PM ET

https://bit.ly/3kAh65M

QI Director's Guide to UDS Review

Tuesday, December 15 1:00 – 2:30 PM ET

https://bit.ly/3oAlEui

* Because of the rapidly changing health environment, these webinars may be subject to change to better meet the needs of our users.

Contact Information





LuAnn Kimker, RN, MSN

Vice President of Clinical Innovation Azara Healthcare LuAnn.Kimker@azarahealthcare.com